Cynthia M Shafer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10828746/publications.pdf

Version: 2024-02-01

31 papers	1,108 citations	394421 19 h-index	434195 31 g-index
36 all docs	36 docs citations	36 times ranked	1801 citing authors

#	Article	IF	Citations
1	Drug discovery considerations in the development of covalent inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 33-39.	2.2	167
2	Design, Structureâ"Activity Relationships and in Vivo Characterization of 4-Amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A Novel Class of Receptor Tyrosine Kinase Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 278-292.	6.4	130
3	Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor. ACS Medicinal Chemistry Letters, 2017, 8, 1116-1121.	2.8	84
4	Design and Synthesis of Orally Bioavailable Benzimidazoles as Raf Kinase Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 7049-7052.	6.4	73
5	Novel Potent and Selective Inhibitors of p90 Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven Cancers. Molecular Cancer Research, 2014, 12, 803-812.	3.4	60
6	Discovery of Potent and Selective RSK Inhibitors as Biological Probes. Journal of Medicinal Chemistry, 2015, 58, 6766-6783.	6.4	50
7	Oxidative Rearrangement of 2-Substituted Oxazolines. A Novel Entry to 5,6-Dihydro-2H-1,4-oxazin-2-ones and Morpholin-2-ones. Journal of Organic Chemistry, 1996, 61, 2044-2050.	3.2	45
8	First Total Synthesis of Bengazole Aâ€. Journal of Organic Chemistry, 1999, 64, 4995-4998.	3.2	44
9	Monosubstituted Oxazoles. 1. Synthesis of 5-Substituted Oxazoles by Directed Alkylation. Journal of Organic Chemistry, 1998, 63, 551-555.	3.2	43
10	Design and structureâ€"activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3595-3599.	2.2	39
11	Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma. ACS Medicinal Chemistry Letters, 2015, 6, 961-965.	2.8	37
12	4-(1H-Indazol-5-yl)-6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4482-4485.	2.2	31
13	Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3. Journal of Medicinal Chemistry, 2017, 60, 8482-8514.	6.4	30
14	Synthesis of the C1î—¸C9 core of bengazole A: Harnessing the ambident nucleophilicity of 2-lithiooxazole. Tetrahedron Letters, 1998, 39, 2903-2906.	1.4	26
15	3D Pharmacophore Model-Assisted Discovery of Novel CDC7 Inhibitors. ACS Medicinal Chemistry Letters, 2011, 2, 720-723.	2.8	22
16	A Practical Synthesis of 1,3-Oxazole. Heterocycles, 2000, 53, 1167.	0.7	21
17	2-Amino-7-substituted benzoxazole analogs as potent RSK2 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1592-1596.	2.2	21
18	Mechanism of SeO2 promoted oxidative rearrangement of 2-substituted oxazolines to dihydrooxazinones: Isotopic labeling and kinetic studies. Tetrahedron, 1996, 52, 14475-14486.	1.9	20

#	Article	IF	Citations
19	Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug Design. Journal of Medicinal Chemistry, 2016, 59, 3034-3045.	6.4	20
20	Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3286-3289.	2.2	19
21	3-Benzimidazol-2-yl-1H-indazoles as potent c-ABL inhibitors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3789-3792.	2.2	18
22	Design and synthesis of 6,6-fused heterocyclic amides as raf kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1678-1681.	2.2	17
23	Synthesis and structureâ€“activity relationships of bengazole A analogs. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2928-2930.	2.2	15
24	Design and structureâ€“activity relationship of heterocyclic analogs of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones as inhibitors of receptor tyrosine kinases. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2247-2251.	2.2	12
25	Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors. ACS Medicinal Chemistry Letters, 2018, 9, 746-751.	2.8	11
26	Practical synthesis of 2,6-dideoxy-d-lyxo-hexose (â€œ2-deoxy-d-fucoseâ€) from d-galactose. Carbohydrate Research, 1998, 310, 223-228.	2.3	10
27	Design and Synthesis of Orally Bioavailable Benzimidazole Reverse Amides as Pan RAF Kinase Inhibitors. ACS Medicinal Chemistry Letters, 2014, 5, 989-992.	2.8	10
28	Design and synthesis of potent RSK inhibitors. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3197-3201.	2.2	10
29	LHMDS mediated tandem acylationâ€“cyclization of 2-aminobenzenecarbonitriles with 2-benzymidazol-2-yl acetates: a short and efficient route to the synthesis of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones. Tetrahedron Letters, 2006, 47, 657-660.	1.4	8
30	Imidazo[1,2- a]pyridin-6-yl-benzamide analogs as potent RAF inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 5221-5224.	2.2	8
31	Discovery and optimization of novel pyridines as highly potent and selective glycogen synthase kinase 3 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126930.	2.2	7